Zevra Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Neil McFarlane

İcra Kurulu Başkanı

US$3.4m

Toplam tazminat

CEO maaş yüzdesi	4.6%
CEO görev süresi	1.2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.5yrs
Yönetim Kurulu ortalama görev süresi	1.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Neil McFarlane'un ücretlendirmesi Zevra Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$90m
Jun 30 2024	n/a	n/a	-US$67m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$3m	US$158k	-US$46m

Tazminat ve Piyasa: Neil 'nin toplam tazminatı ($USD 3.45M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.01M ).

Tazminat ve Kazançlar: Neil şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Neil McFarlane (51 yo)

1.2yrs

Görev süresi

US$3,445,231

Tazminat

Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He served as Independent Director at...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Neil McFarlane	President	1.2yrs	US$3.45m	Veri yok
R. Clifton	CFO, Secretary & Treasurer	9.5yrs	US$2.26m	0.035% € 152.6k
Joshua Schafer	Chief Commercial Officer & Executive VP of Business Development	1.9yrs	US$1.82m	0.0066% € 28.9k
Nichol Ochsner	Vice President of Investor Relations & Corporate Communications	2.3yrs	Veri yok	Veri yok
Rahsaan Thompson	Chief Legal Officer	less than a year	Veri yok	Veri yok
Alison Peters	Chief People Officer	less than a year	Veri yok	Veri yok
Christopher Lauderback	Senior Vice President of Manufacturing	1.9yrs	Veri yok	Veri yok
Rene Braeckman	Senior Vice President of Clinical Development	1.9yrs	Veri yok	Veri yok
Daniel Gallo	Senior Vice President of Medical Affairs & Advocacy	1.9yrs	Veri yok	Veri yok
Adrian Quartel	Chief Medical Officer	less than a year	Veri yok	Veri yok
Gerald Orehostky	Senior Vice President of Regulatory Affairs & Quality	less than a year	Veri yok	Veri yok
Tanya Hayden	Senior VP & Chief of Staff	less than a year	Veri yok	Veri yok

1.5yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: 1GDA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Neil McFarlane	President	1.2yrs	US$3.45m	Veri yok
Wendy Dixon	Independent Director	1.7yrs	US$274.00k	0% € 0
Douglas Calder	Independent Director	1.7yrs	US$258.02k	0% € 0
Tamara Favorito	Independent Chair	3.3yrs	US$324.39k	0.0014% € 6.0k
Donald Jasinski	Member of Scientific and Medical Advisory Board	no data	Veri yok	Veri yok
John Bode	Independent Director	1.7yrs	US$264.31k	0.056% € 247.9k
Corey Watton	Independent Director	1.7yrs	US$260.67k	0.0028% € 12.4k
Barney Bishop	Chairman of Scientific and Medical Advisory Board	17.9yrs	Veri yok	Veri yok
Robert Findling	Member of Scientific & Medical Advisory Board	no data	Veri yok	Veri yok
Jeffrey Gudin	Co-Chair of Physician Advisory Council	11.2yrs	Veri yok	Veri yok
Srinivas Nalamachu	Co-Chair of Physician Advisory Council	11.2yrs	Veri yok	Veri yok
Thomas Anderson	Independent Director	1.3yrs	US$243.04k	0.037% € 165.3k

1.7yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1GDA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/25 14:46
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Zevra Therapeutics, Inc. 16 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Dewey Steadman	Canaccord Genuity
Sumant Satchidanand Kulkarni	Canaccord Genuity
Louise Chen	Cantor Fitzgerald & Co.

Zevra Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zevra Therapeutics, Inc. Announces Departure of Executives

High number of new directors

Independent Director recently bought €54k worth of stock

Zevra Therapeutics, Inc. Expands Executive Leadership Team

Zevra Therapeutics, Inc., Annual General Meeting, May 13, 2024

Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors

Recent updates

Zevra Therapeutics, Inc. Announces Departure of Executives

Zevra Therapeutics, Inc. Announces U.S. Commercial Availability of MIPLYFFA for Treatment of Niemann-Pick Disease Type C

Third quarter 2024 earnings released: US$0.69 loss per share (vs US$0.40 loss in 3Q 2023)

Zevra Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

High number of new directors

Second quarter 2024 earnings released: US$0.48 loss per share (vs US$0.15 loss in 2Q 2023)

Zevra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000005 million.

New major risk - Shareholder dilution

Zevra Therapeutics, Inc. Announces FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Zevra Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Independent Director recently bought €54k worth of stock

Zevra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Zevra Therapeutics, Inc. Expands Executive Leadership Team

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia At Sleep 2024 Annual Meeting

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.34 loss in 1Q 2023)

Zevra Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Zevra Therapeutics, Inc., Annual General Meeting, May 13, 2024

Full year 2023 earnings released: US$1.30 loss per share (vs US$1.21 loss in FY 2022)

Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia

Zevra Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast breakeven date pushed back to 2026

Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors

Zevra Therapeutics, Inc. Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Zevra Therapeutics, Inc. Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

New minor risk - Shareholder dilution

No longer forecast to breakeven

Zevra Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zevra Therapeutics, Inc. Announces Executive Changes

Zevra Therapeutics, Inc. Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of Sdx, the Sole Active Pharmaceutical Ingredient in Kp1077, in Healthy Volunteers At Psych Congress 2023

New minor risk - Profitability

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.70 loss in 2Q 2022)

No longer forecast to breakeven

Zevra Therapeutics, Inc. Announces Board Changes

High number of new directors

First quarter 2023 earnings released: US$0.34 loss per share (vs US$0.054 loss in 1Q 2022)

Zevra Therapeutics, Inc. Announces Change of CEO, Effective June 1, 2023

Full year 2022 earnings released: US$1.21 loss per share (vs US$2.11 loss in FY 2021)

KemPharm, Inc. Appoints Daniel Gallo as Senior Vice President of Medical Affairs and Advocacy

KemPharm, Inc., Annual General Meeting, Apr 25, 2023

KemPharm, Inc. Announces Promotion of Sven Guenther to Chief Scientific Officer and Christal Mickle to Chief Product Development Officer

KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

KemPharm, Inc. Appoints Christopher Posner as New Independent Director

KemPharm, Inc. Announces That the U.S. Food and Drug Administration (The FDA) Grants the Orphan Drug Designation to Serdexmethylphenidate

Third quarter 2022 earnings released: US$0.19 loss per share (vs US$0.05 loss in 3Q 2021)

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.19 loss per share (vs US$0.05 loss in 3Q 2021)

Kempharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (Sdx)

Second quarter 2022 earnings released: US$0.70 loss per share (vs US$0.40 loss in 2Q 2021)

Forecast breakeven date pushed back to 2024

KemPharm, Inc.(NasdaqGS:KMPH) dropped from Russell Microcap Value Index

First quarter 2022 earnings released: US$0.054 loss per share (vs US$2.49 loss in 1Q 2021)

KemPharm, Inc., Annual General Meeting, Jun 28, 2022

KemPharm, Inc. Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

Forecast breakeven date pushed back to 2023

Kempharm, Inc. Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate

Forecast breakeven date pushed back to 2023

Full year 2021 earnings released: US$2.11 loss per share (vs US$3.21 loss in FY 2020)

KemPharm, Inc. Completes KP1077 Pre-IND Meeting Process with FDA

KemPharm, Inc. (NasdaqGS:KMPH) announces an Equity Buyback for $50 million worth of its shares.

Kempharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose Sdx”

Forecast to breakeven in 2022

Third quarter 2021 earnings released: US$0.05 loss per share (vs US$0.68 loss in 3Q 2020)

Forecast breakeven pushed back to 2023

Second quarter 2021 earnings released: US$0.37 loss per share (vs US$0.21 profit in 2Q 2020)

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc

Forecast breakeven pushed back to 2022